Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Sungrow String Inverter SG 6.0 RS
Contact UsSuitable for 50Hz/60Hz grid, could be used in Asia, Africa,South America,Australia and Europe. Available for hand installation, no need for liftingmachinery assistance.
-
Metal cloths
Contact UsYancheng Zhongming New Materials Co., Ltd. is located in Yancheng City, Jiangsu Province.
-
1408Wh Power Station with jump starter
Contact UsUnleash power with our 1408Wh Power Station & Jump Starter.
-
321 Stainless Steel Tube
Contact UsGrade: 200series, 300series, 400series, etc
Standard: ASTM/DIN/GB/JIS/AISI
Surface: No.1/2B/BA/NO.4/6K/8K/HL(Hairline)/PVC
Payment: Term T/T; L/C; Western Union; Paypal
Delivery Time: 7-15 days upon receipt of the deposit
Package: Standard Export Packing or As Customers Requirement
Reviews
There are no reviews yet.